• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Unicycive Therapeutics Inc.

    5/5/26 9:02:03 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UNCY alert in real time by email
    S-8 1 ea0288752-s8_unicycive.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on May 5, 2026

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    UNICYCIVE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   81-3638692
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    1975 W. El Camino Real, Suite 204

    Mountain View, CA

    (650) 351-4495

    (Address of principal executive offices) (Zip Code)

     

    Unicycive Therapeutics, Inc. Second Amended and Restated Omnibus 2021 Equity Incentive Plan

    (Full title of the plan)

     

    Shalabh Gupta, M.D.

    Chief Executive Officer

    Unicycive Therapeutics, Inc.

    1975 W. El Camino Real, Suite 204

    Mountain View, CA

    (650) 351-4495

    (Name and Address of agent for service)

     

    (650) 351-4495

    (Telephone number, including area code, of agent for service)

     

    With copies to:

     

    Jeffrey Fessler

    Sheppard, Mullin, Richter & Hampton LLP

    30 Rockefeller Plaza

    New York, NY 10012

    Tel: (212) 653-8700

    Fax: (212) 653-8701

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    This Registration Statement will become effective upon filing in accordance with Rule 462(a) under the Securities Act.

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8, relating to the Unicycive Therapeutics, Inc. Second Amended and Restated Omnibus 2021 Equity Incentive Plan (the “2021 Plan”) of Unicycive Therapeutics, Inc., Inc. (the “Company”), is being filed for the purpose of registering additional securities of the same class as other securities for which Registration Statements on Form S-8 relating to the 2021 Plan have previously been filed and is effective and consists only of those items required by General Instruction E to Form S-8. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-275965, filed with the Securities and Exchange Commission on December 8, 2023, by the Company, relating to the 2021 Plan; and (ii) the Registration Statement on Form S-8 File No. 333-286305 filed with the Securities and Exchange Commission on April 1, 2025 relating to the 2021 Plan; (collectively, the “Prior Registration Statements”), except for Items 3 and 8, which are being updated by this Registration Statement.

     

    This Registration Statement is being filed for the purpose of registering an additional 884,570 shares of common stock, par value $0.001 per share (“Common Stock”) that were reserved for issuance under the 2021 Plan. In addition, the 2021 Plan provides that shares issued under the 2021 Plan that are forfeit or expire are available for future grants of awards under the 2021 Plan and an additional 88,450 shares of Common Stock are being registered hereunder for that purpose, for an aggregate of 973,020 shares of Common Stock being registered hereunder.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of documents by reference.

     

    The following documents filed by the Company with the Securities and Exchange Commission (“SEC”) pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

      ● The Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026;

     

      ● The Company’s Current Reports on Form 8-K filed with the SEC on April 6, 2026 (other than any portions thereof deemed furnished and not filed);

     

      ● The description of the Company’s common stock par value $0.001 per share, contained in Exhibit 4.4 to our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026, including any amendment or report filed for the purpose of updating such description;  and

     

      ● All other reports and documents filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    II-1

     

     

    Item 8. Exhibits.

     

    Exhibit Number   Description
    3.1   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.4 to Form S-1 filed on May 21, 2021)
    3.2   Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 26, 2024).
    3.3   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated June 18, 2025, (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 20, 2025)
    3.4   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.5 to Form S-1 filed on May 21, 2021)
    4.1   Specimen stock certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4,1 to Form S-1 filed on May 21, 2021)
    5.1*   Opinion of Sheppard, Mullin, Richter & Hampton LLP
    10.1   Unicycive Therapeutics, Inc. Second Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit C to Definitive Proxy Statement filed on April 26, 2024)
    23.1*   Consent of Grassi & Co., CPAs, P.C., independent registered public accounting firm
    23.2*   Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1)
    24.1   Power of Attorney (included on signature page)
    107   Filing Fee Table

     

    * Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Altos, State of California, on the 5th day of May, 2026.

     

      UNICYCIVE THERAPEUTICS, INC.
         
      By: /s/ Shalabh Gupta
        Shalabh Gupta
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Shalabh Gupta, his or her true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities to sign any or all amendments (including, without limitation, post-effective amendments) to this Registration Statement, any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and any or all pre- or post-effective amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or substitutes for him, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE   TITLE   DATE
             
    /s/ Shalabh Gupta   Chief Executive Officer, President and Chairman   May 5, 2026
    Shalabh Gupta   (Principal Executive Officer)    
             
    /s/ John Townsend   Chief Financial Officer   May 5, 2026
    John Townsend   (Principal Financial and Accounting Officer)    
             
    /s/ Sandeep Laumas   Director   May 5, 2026
    Sandeep Laumas, M.D.        
             
    /s/ Saraswati Kenkare-Mitra   Director   May 5, 2026
    Saraswati Kenkare-Mitra          

     

    II-3

     

    Get the next $UNCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UNCY

    DatePrice TargetRatingAnalyst
    5/1/2026$22.00Buy
    B. Riley Securities
    4/21/2025$6.00Buy
    Guggenheim
    4/4/2024$9.00Overweight
    Piper Sandler
    8/9/2021$13.50Buy
    Roth Capital
    More analyst ratings

    $UNCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kenkare-Mitra Sara

    4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

    5/21/26 4:30:25 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Gupta Shalabh K.

    4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

    5/21/26 4:30:27 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Corporate Strategy Jermasek Douglas

    4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

    5/20/26 4:30:25 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    SEC Filings

    View All

    Unicycive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

    6/5/26 4:19:29 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Unicycive Therapeutics Inc.

    S-3 - Unicycive Therapeutics, Inc. (0001766140) (Filer)

    6/5/26 4:15:39 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

    SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    5/15/26 4:45:29 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Unicycive Therapeutics with a new price target

    B. Riley Securities initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $22.00

    5/1/26 8:06:59 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

    Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

    4/21/25 8:39:22 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Unicycive Therapeutics with a new price target

    Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00

    4/4/24 8:18:34 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

    U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities continue in anticipation of the potential commercial launch of OLC MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. "As we approach the June 29th PDUFA target action date, we remain opti

    5/12/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

    LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investi

    4/9/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Leadership Updates

    Live Leadership Updates

    View All

    Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

    LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh

    9/6/23 7:03:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

    LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal

    10/26/21 7:30:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Financials

    Live finance-specific insights

    View All

    Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

    U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities continue in anticipation of the potential commercial launch of OLC MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. "As we approach the June 29th PDUFA target action date, we remain opti

    5/12/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

    -   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end -   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders -   Ended Q3 with $42.7 million of cash with expected runway into 2027 LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for t

    11/12/25 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 5:46:12 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care